Atlas Trials

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Clinical trial NCT03989362 · COMPLETED

Trial details

NCT number
NCT03989362
Sponsor
Jounce Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2019-06-06
Primary completion
2022-03-15
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.